findmyKOL

Anne Tsao, MD

Enriched profile

Vice President, Faculty & Academic Affairs (CAO Office); Professor (Term-Tenure), Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine; Director, Mesothelioma Program; Director, Thoracic Chemo-Radiation Program · The University of Texas MD Anderson Cancer Center

ORCIDNPI
Region🇺🇸 Houston, TX · South Central · United StatesSpecialtyMedical OncologyFocusLymphoma+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2018–2026

Anne Tsao is Vice President, Faculty & Academic Affairs (CAO Office); Professor (Term-Tenure), Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine; Director, Mesothelioma Program; Director, Thoracic Chemo-Radiation Program at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 591 publications with 56,665 citations (h-index 86); ClinicalTrials.gov lists 13 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Anne S. Tsao, MD, is Vice President, Faculty & Academic Affairs (CAO Office) at The University of Texas MD Anderson Cancer Center. The public record shows 591 publications with 56,665 citations (h-index 86), centered on Lymphoma, Lung Cancer (NSCLC/SCLC), Sarcoma. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 17 companies, 2 NIH-funded awards (2018–2026).

  • Most recent indexed publication: 2026 · Journal of clinical oncology
  • Top research focus: Lymphoma
  • 13 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 17 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Mesothelioma6 trialsMesothelioma, Malignant4 trialsLung Cancer (NSCLC/SCLC)4 trialsSarcoma1 trialComa1 trialCarcinoma, Small Cell1 trialLymphoma1 trialMultiple Myeloma1 trialHead & Neck Cancer1 trialNeoplasms, Squamous Cell1 trialSmall Cell Lung Carcinoma1 trialThymoma1 trial

Research focus

OpenAlex concept fingerprint
LymphomaLung Cancer (NSCLC/SCLC)SarcomaHead & Neck CancerMultiple Myeloma

Drugs & molecules

across trials, industry payments and publications
Alecensageneric · AlectinibClinical trialsIndustry payments6PublicationsTecentriqgeneric · AtezolizumabClinical trialsIndustry payments6PublicationsTagrissogeneric · OsimertinibClinical trialsIndustry payments4Publications

Works with

trial sponsors and companies reporting payments
Gilead Sciences, Inc.Clinical trialsIndustry payments16AstraZeneca Pharmaceuticals LPClinical trialsIndustry payments10M.D. Anderson Cancer CenterClinical trials9Industry payments

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
591publications

Distinct works indexed by OpenAlex, matched via ORCID; 17 in PubMed.

56,665citations

Total citations across indexed works.

86h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
13clinical trials

Investigator role on registered studies.

View trials
17companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 2018–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Kinase inhibitor100%
    Tagrisso81%Erlotinib Hcl19%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

2 NIH research awards on record, funded 20182026 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/anne-tsao-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/anne-tsao-md-mba

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • ResearchGate

    researchgate.net/scientific-contributions/Anne-S-Tsao-2295719983

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net
1 more verified account behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • Other

    cancergrace.org/post/round-table-drs-anne-tsao-and-alex-farivar-part-2-mesothelioma

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancergrace.org
  • Other

    streaming.mdanderson.org/transcript/cl-mesothelioma-new-advances.html

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →streaming.mdanderson.org
  • Other

    iaslc.org/iaslc-news/lung-cancer-considered/state-mesothelioma-treatment-dr-anne-tsao

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org
4 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MBA

    MIT Sloan School of Management

    2021
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • MD

    University of Chicago Pritzker School of Medicine

    1998
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • BS

    Molecular Biology, Massachusetts Institute of Technology

    1994
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Board Certified

    Internal Medicine and Medical Oncology, American Board of Internal Medicine

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mesotheliomahub.com
  • Internship and residency

    Indiana University; fellowship, The University of Texas MD Anderson Cancer Center

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mesotheliomahub.com

Editorial & leadership roles

journal and society appointments
  • Editorial Board Member

    Journal of Healthcare Management/ACHE

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Specialty Editor

    ASCO Cancer.Net

    2021
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Associate Editor

    NEJM Journal Watch

    2020
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
6 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
  • Fellow

    American Society of Clinical Oncology (FASCO)

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Fellow

    American College of Healthcare Executives (FACHE)

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
9 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Chair

    Clinical Research Committee, MD Anderson

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mdanderson.org

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.